A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
暂无分享,去创建一个
Z. Ram | J. Jääskeläinen | M. Westphal | D. Hilt | I. Whittle | P. Warnke | E. Bortey | R. Olivares | P. Delavault
[1] R. Coleman,et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2-a preliminary report , 2005, Journal of Neuro-Oncology.
[2] H. Reulen,et al. Factors affecting the extension of peritumoural brain oedema. A CT-study , 2005, Acta Neurochirurgica.
[3] R. Merchant,et al. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes , 1990, Journal of Neuro-Oncology.
[4] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[5] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[6] G. Fuller. Pathology and Genetics of Tumours of the Nervous System (World Health Organization Classification of Tumours). , 2001 .
[7] N. Rainov. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.
[8] H. Engelhard,et al. Gene therapy for brain tumors , 2000, Current oncology reports.
[9] W. Yung,et al. Clinical trial end points in malignant glioma: need for effective trial design strategy. , 2000, Seminars in oncology.
[10] M. Prados,et al. Biology and treatment of malignant glioma. , 2000, Seminars in oncology.
[11] Webster K. Cavenee,et al. Pathology and genetics of tumours of the nervous system. , 2000 .
[12] M. Westphal,et al. Local control of gliomas: the next best step--a good step? , 1999, Frontiers of radiation therapy and oncology.
[13] G. Giuliani,et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas , 1997, Cancer.
[14] R. Martuza,et al. Act locally, think globally , 1997, Nature Medicine.
[15] E. Oldfield,et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.
[16] Z. Ram,et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells , 1997, Nature Medicine.
[17] H Kalimo,et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. , 1997, Neurosurgery.
[18] D. Andrews,et al. Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. , 1997, Neurosurgery.
[19] P. Wersäll,et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma , 1997, Cancer Immunology, Immunotherapy.
[20] R. Merchant,et al. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. , 1997, Neurological research.
[21] J Hildebrand,et al. Management of malignant brain tumors. , 1997, European neurology.
[22] M. Westphal,et al. Glioma invasion in the central nervous system. , 1996, Neurosurgery.
[23] K. Willecke,et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. Willingham,et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. , 1995, Cancer research.
[25] P F Morrison,et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.
[26] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[27] G. Lesser,et al. The chemotherapy of high-grade astrocytomas. , 1994, Seminars in oncology.
[28] A. Olivi,et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. , 1994, Journal of neurosurgery.
[29] J. Cairncross. Aggressive oligodendroglioma: a chemosensitive tumor. , 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[30] M. Salcman. The value of cytoreductive surgery. , 1994, Clinical neurosurgery.
[31] U. Bogdahn,et al. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. , 1993, Journal of neurosurgery.
[32] H. Fine,et al. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[33] A. Kaye,et al. Chemotherapy of gliomas. , 1992, Current opinion in neurology and neurosurgery.
[34] Z. Ram,et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.
[35] S. Green,et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. , 1992, Journal of neurosurgery.
[36] M. Westphal,et al. Superselective intraarterial cisplatin application for recurrent malignant gliomas , 1992 .
[37] D. Constam,et al. Modulation of the immune response by transforming growth factor beta. , 1992, International archives of allergy and immunology.
[38] M. Westphal,et al. Lymphokine-activated killer cells, interleukin-2 and tumour necrosis factor α in malignant glioma : clinical and laboratory findings , 1991 .
[39] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[40] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[41] Fred H. Hochberg,et al. Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.
[42] D Riddoch,et al. Neoplasms of the central nervous system. , 1977, The Practitioner.